Humuline Nph Patroon

Humuline Nph Patroon is a prescription insulin product that contains recombinant human insulin (Insulin Human) as its active ingredient. It is supplied in an injectable form for subcutaneous administration, with the specific strength not disclosed in the available data. Marketed in the European Union, this insulin belongs to the intermediate‑acting (NPH) category and is used under medical supervision for diabetes management and glycemic control through individualized therapy.

Humuline Nph Patroon is indicated for the long‑term management of blood glucose in adults with diabetes.

- Type 1 diabetes mellitus (insulin‑dependent). - Type 2 diabetes mellitus (when oral agents insufficient). - As part of basal insulin regimen combined with rapid‑acting insulin. - To provide basal insulin coverage during periods of fasting or between meals. - May be used in hospital settings for glucose control under physician direction. - In patients requiring a stable, intermediate‑acting insulin profile to reduce nocturnal hyperglycemia.

Adverse reactions reported with Humuline Nph Patroon are generally consistent with those of other intermediate‑acting insulins.

Common: - Mild hypoglycemia, especially if meals are missed or delayed. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy (localized fat accumulation or loss) at the injection site. - Transient weight gain due to fluid retention. - Nausea or headache shortly after injection.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Persistent hyperglycemia indicating possible insulin resistance or dosing error. - Edema or heart failure exacerbation in susceptible patients. - Unexplained visual disturbances suggesting acute hyperglycemia. - Anaphylactic shock requiring emergency medical attention.

When prescribing Humuline Nph Patroon, clinicians should consider several precautionary factors to ensure safe use.

- Assess renal and hepatic function, as impairment may alter insulin clearance. - Review patient’s history of hypoglycemia unawareness before initiating therapy. - Adjust dose during periods of illness, pregnancy, or significant weight change. - Monitor for signs of cardiovascular strain, especially in patients with heart failure. - Educate patients on proper injection technique to reduce lipodystrophy risk. - Avoid use in individuals with known hypersensitivity to human insulin or any formulation excipients.

Humuline Nph Patroon may interact with other medications that affect glucose metabolism or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulins without dose adjustment, which can cause severe hypoglycemia. - Beta‑blockers that mask hypoglycemia symptoms. - High‑dose corticosteroids that markedly increase blood glucose.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that may potentiate hypoglycemia. - ACE inhibitors or ARBs, which can enhance insulin sensitivity. - Alcohol consumption, as it can unpredictably affect glucose levels. - Thyroid hormones, which may alter insulin requirements. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may affect renal function and insulin clearance.